Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD (HeartBeet)

April 5, 2023 updated by: David N. Proctor, PhD

Effects of Dietary Nitrate Supplementation on Coronary Blood Flow and Walking Performance in Peripheral Arterial Disease

In this study the investigators will test the hypothesis that short-term consumption of inorganic nitrate (supplied in concentrated beetroot juice) enhances coronary blood flow responses, large artery hemodynamics, and leg oxygenation/exercise tolerance in patients with peripheral arterial disease (PAD). Understanding and improving blood flow regulation in the heart and skeletal muscles of patients with PAD is important because exercise triggers symptoms of leg pain and substantially raises blood pressure and myocardial demand in these patients.

Study Overview

Status

Active, not recruiting

Detailed Description

Peripheral arterial disease (PAD) is a strong predictor of cardiovascular mortality and negatively affects functional capacity and quality of life for as many as 14 million patients in the U.S. alone. One open-label study showed that acute consumption of beetroot juice improved 6 min walk performance, reduced blood pressure, and enhanced leg muscle oxygenation in PAD patients. However, no studies have rigorously confirmed these findings in a double-blind manner, nor have the effects of this supplement been investigated (acutely or short-term) in the coronary circulation of PAD patients.

In addition to studying its effects on graded treadmill walking performance and consequent large artery vasodilation, the present study will examine the effects of short-term beetroot juice consumption (twice/day) on both coronary and leg vasodilator (graded calf flexion) and vasoconstrictor (isometric handgrip, voluntary apnea) responses in patients with PAD. Participants will randomly consume either nitrate-rich or nitrate-depleted beetroot juice with a 7 to 14 day wash-out period between. Effects of beetroot juice consumption on plasma nitrate, nitrite and methemoglobin will also be assessed.

Study Type

Interventional

Enrollment (Anticipated)

12

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Milton S. Hershey Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with peripheral arterial disease (PAD)
  2. Capable of giving informed consent
  3. Men and women age 21- 85 years
  4. Diagnosed with PAD (i.e., ankle-brachial index below 0.9)
  5. Fontaine stage II or less - no pain while resting
  6. Satisfactory history and physical exam

Exclusion Criteria:

  1. Children
  2. Pregnant or nursing women
  3. Patients taking nitroglycerine or nitrate preparations
  4. Patients taking phosphodiesterase inhibitors such as sildenafil or tadalafil
  5. Patients taking proton pump inhibitors
  6. Ejection fraction < 40%
  7. Uncontrolled hypertension
  8. Uncontrolled diabetes
  9. Myocardial infarction within past 6 months or unstable angina
  10. Severe lung disease (i.e., on supplemental oxygen or frequently use rescue inhalers)
  11. Abnormality in hemoglobin or hematocrit or methemoglobin
  12. Impaired renal function
  13. Impaired liver function
  14. History or diagnosis of Barrett's esophagus
  15. Known allergy to beetroot juice or lemon juice
  16. Inability to walk on a treadmill at a moderate pace (2.0 miles/hour)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Beetroot juice (Beet-It Organic Shot)
Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Other Names:
  • Beet-It Organic Shot
Placebo Comparator: Beetroot juice placebo (Beet-It Organic Placebo)
Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Other Names:
  • Beet-It organic placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exercise performance
Time Frame: 5 to 7 days after initiating daily ingestion of beetroot juice
Exercise capacity will be assessed using a graded treadmill walking test to peak exertion with expired gas analysis and determination of peak oxygen uptake, calf muscle oxygenation, blood pressure, claudication onset time, and peak walking time.
5 to 7 days after initiating daily ingestion of beetroot juice

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Coronary vascular function
Time Frame: 4 days after initiating daily ingestion of beetroot juice
Coronary artery (transthoracic ultrasound) blood flow responses to plantar flexion and handgrip exercise.
4 days after initiating daily ingestion of beetroot juice
Leg vascular function
Time Frame: 4 days after initiating daily ingestion of beetroot juice
Popliteal artery and near infrared spectroscopy (NIRS) responses to plantar flexion and handgrip exercise.
4 days after initiating daily ingestion of beetroot juice

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood measures of nitrate absorption and conversion
Time Frame: 4 to 7 days after initiating ingestion of beetroot juice
Venous blood will be withdrawn (venipuncture) for determination of plasma nitrate, nitrite and methemoglobin levels
4 to 7 days after initiating ingestion of beetroot juice

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Urs A Leuenberger, MD, Penn State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2015

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

December 1, 2024

Study Registration Dates

First Submitted

September 15, 2015

First Submitted That Met QC Criteria

September 15, 2015

First Posted (Estimate)

September 18, 2015

Study Record Updates

Last Update Posted (Actual)

April 6, 2023

Last Update Submitted That Met QC Criteria

April 5, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Arterial Disease

Clinical Trials on Beetroot juice

Subscribe